A New Cancer Treatment harnessing the Immune System

Explore

We are developing a safe, effective, immunological-based treatment for a range of hard-to-treat solid tumours

Over the past eight years, Selvax has achieved a major breakthrough in cancer treatment. 

Selvax’s self-vaccine cancer immunotherapy harnesses the body’s anti-tumour immune response. 

By combining two immunological agents approved for human use and administering them directly into the tumour site, we have achieved complete regression of large, chemotherapy-resistant tumours without toxicity.

Successfully tested in animals for eight solid tumours

In successfully treated animals, tumours cleared and did not recur for the remainder of their lives.

Trials demonstrated that treating a tumour in one location in the animal resulted in the destruction of a second tumour in another part of the body.

Tumour Cure Rates in Animal Testing

Treatment without Toxicity

Our innovative approach differs from traditional chemotherapy and radiological treatments in that its goal is to stimulate the patient’s own immune system to kill cancer.

  • Effectively acts as a vaccine preventing cancer recurrence.
  • It is also unique in that the delivery of the two immunological agents is made directly into the tumour and not systemically, thereby minimising the toxic side effects which had previously been an issue for other cancer immunotherapies (or indeed traditional chemotherapy).

Our Current Activities

  • Replicating previous successful small animal trials for a broader range of cancers, and generating samples of immune cells from cured animals for antibody screening.
  • Continuing testing of Selvax immunotherapy in dogs with naturally occurring cancers.
  • Undertaking further animal studies to compare the efficacy of Selvax’s immunotherapy against standard-of-care and FDA approved checkpoint inhibitors.
  • Continuing preparations for first in-human testing of Selvax therapy at either an Australian or European clinical trial site (ongoing).

Research Collaborators

The Curtin Health Innovation Research Institute

Curtin University in Western Australia is Selvax’s principal research partner and undertakes contract research on Selvax’s behalf. Curtin is the largest university in West Australia and is ranked in the top 1% of universities worldwide.

The Curtin Health Innovation Research Institute (CHIRI) is located on Curtin University’s Bentley campus and operates within a $35 million facility that provides more than 150 scientists and research students with access to state-of-the-art technology for advanced gene, protein and cell analysis.